Company news

Share this article:
Pfizer announced that it has entered into a $15 million dollar collaboration with the University of Pennsylvania School of Medicine. The partnership will include collaborations between Pfizer and the university in the areas of scientific research, clinical development and clinical care and policy. Under the terms of the agreement, Pfizer will pay Penn $15 million over a three-year period, during which time scientists from Pfizer and Penn's School of Medicine will work together on several projects of mutual interest including basic and translational research addressing several therapeutic areas. Project proposals will be solicited and reviewed by a committee with representation from both parties. The initial emphasis of the collaboration will focus on the neurosciences and oncology, but may expand to other areas, Pfizer said in a statement.

Omnicom's digital and CRM-intensive STAR Marketing network launched a healthcare offering. STAR Healthcare will offer “integrated, personalized” direct to patient programs under the guidance of managers to be announced in two unique positions: those of “patient advocate” and “client champion.”

Ketchum launched Well Connected, a “cross-practice health and wellness specialty” aimed at leveraging the shop's expertise in health and wellness, influencer relationships and proprietary research in food and nutrition, healthcare and brand. In addition to research, the practice also offers clients a partnership with the National Senior Games Association and supermarket and branding expert Phil Lempert.  
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.